|
Common Diabetic Therapy Reduces Risk of Pancreatic
Cancer
Reported August 06, 2009
(Ivanhoe Newswire) -- Taking the most commonly-prescribed
anti-diabetic drug, metformin, reduces the risk of developing pancreatic
cancer by 62 percent, according to research from The University of Texas M.
D. Anderson Cancer Center.
"This is the first epidemiological study of metformin in the cancer
population, and it offers an exciting direction for future chemoprevention
research for a disease greatly in need of both treatment and prevention
strategies," Donghui Li, Ph.D., lead author and professor in M. D.
Anderson's Department of Gastrointestinal Medical Oncology was quoted as
saying.
According to Li, more than 35 million prescriptions for metformin, which is
taken orally, are filled annually. It is most often given to type 2 diabetic
patients who are obese or who have insulin resistance.
"Metformin works by increasing the cellular sensitivity to insulin and
decreasing its level circulating in diabetics. Insulin also seems to have a
growth-promoting effect in cancer," said Li. "Metformin activates the AMP
kinase, which is a cellular energy sensor. Recent publications have
described that AMP kinase also plays an important role in the development of
cancer by controlling cell division and growth."
"Knowing that diabetes is a risk factor for the development of pancreatic
cancer and that 10 percent of such cancers are associated with diabetes, we
wanted to better understand the specific association between different
anti-diabetic therapies and this lethal disease," explained Li.
For the case control study, the researchers enrolled 1,838 participants --
973 patients with pancreatic cancer treated at M. D. Anderson between 2004
and 2008 -- to compare with 863 cancer-free individuals, all companions of
M. D. Anderson patients. Of all participants, 259 patients and 109 controls
were diabetics.
The groups were matched by age, race and sex. Personal interviews were
conducted to collect such information as smoking history, family history of
cancer, alcohol use and body mass index. Diabetics were also asked about
their anti-diabetic medication history.
The researchers found that diabetics who took metformin alone or in any
combination with other diabetic therapies had a 62 percent reduced risk of
developing pancreatic cancer, compared to those who never used the drug.
Li noted the study is not without limitations, including the relatively
small size of the study's diabetic population. She hopes the research will
be replicated using a larger sample size. Still, the findings present the
immediate opportunity to explore metformin as a chemopreventive agent.
Pancreatic cancer is the fourth leading cause of cancer death in this
country. According to the American Cancer Society, more than 42,470 people
will be diagnosed and 35,240 will likely die from the disease in 2009. The
median survival for patients with the disease is less than 10 months and the
five-year survival rate is less than five percent.
"While further validation is needed, our findings show metformin's potential
as a chemopreventive agent," said Li. "Currently, once pancreatic cancer is
diagnosed, we have few successful therapeutic agents to offer our patients,
so obviously, for those at greatest risk, a preventive mechanism such as
metformin would be a welcome option."
In a corresponding editorial, Yu-Xiao Yang, M.D. of the University of
Pennsylvania School of Medicine noted that the American Diabetes Association
and the European Association for the Study of Diabetes have both recommended
the inclusion of metformin for all type 2 diabetes patients without
contraindications and notes that the possible chemopreventive properties of
the drug "may provide an additional incentive for patients and physicians to
follow this recommendation."
SOURCE: Gastroenterology, August 1, 2009 |
